Who are Aduro Biotech's investors?

Aduro Biotech's investors include Foresite Capital, ACCELERATOR LIFE SCIENCE PARTNERS, Franklin Templeton, OrbiMed.

How much funding has Aduro Biotech raised?

Aduro Biotech has disclosed $92M raised across 2 rounds.

Who acquired Aduro Biotech?

Aduro Biotech was acquired by Chinook Therapeutics.

Where is Aduro Biotech headquartered?

Aduro Biotech is headquartered in Berkeley, US.

Aduro Biotech

Unicorn exit · $3.5Bacquired by Chinook Therapeutics

Berkeley, US · Founded 2011 · Delaware corporation · 4 known investors

Find your way into Aduro Biotech

Acquired by Chinook Therapeutics October 2020 · $3.5B (Novartis acquired Chinook Therapeutics (the merged company) for $3.5 billion in 2023) · source ↗

Aduro Biotech was a Berkeley, CA clinical-stage biopharmaceutical company developing cancer immunotherapies, including STING-pathway agonists and Listeria-based vaccine platforms derived from UC Berkeley research.

Biotech

Founders & leadership

Thomas DubenskyExecutive

Dirk G. BrockstedtExecutive

Stephen IsaacsExecutive

Jennifer LewExecutive

Gregory W. SchaferExecutive

Board

Gerald David ChanBoard director

Frank McCormickBoard director

Ross HaghighatBoard director

William GreenmanBoard director

Stephanie O'BrienBoard director

Investors · 4

Foresite CapitalWest Hollywood

ACCELERATOR LIFE SCIENCE PARTNERSreportedSeattle

Franklin TempletonreportedSan Mateo

OrbiMedreportedNew York · $1M – $75M

Reported raises · per SEC filings

Form D private placements

$92M disclosed across 2 rounds · 2014

▶$51.4MraisedJan 2015 · 28 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Frank McCormickDirector
Gerald David ChanDirector
Thomas DubenskyExecutive Officer
Dirk G. BrockstedtExecutive Officer
Ross HaghighatDirector
William GreenmanDirector
Stephanie O'BrienDirector
Stephen IsaacsExecutive Officer, Director
Jennifer LewExecutive Officer
Gregory W. SchaferExecutive Officer

Offering amount: $51.4M
Amount sold: $51.4M
Sales commissions: $2.4M
Placement agents: Leerink Partners LLC
First sale: Dec 2014
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$40.6MraisedJun 2014 · 25 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Stephanie O'BrienDirector
Frank McCormickDirector
Jennifer LewExecutive Officer
Stephen IsaacsExecutive Officer, Director
Gregory SchaferExecutive Officer
Gerald David ChanDirector
William GreenmanDirector
Ross HaghighatDirector

Offering amount: $40.6M
Amount sold: $40.6M
First sale: May 2014
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Chinook Raises $106 Million Ahead of Merger with Aduro Biotech - Global Genesglobalgenes.org · Aug 2020

Aduro Biotech helps launch new immunotherapy, vaccine effort | Molecular and Cell Biologymcb.berkeley.edu · Mar 2016

Aduro Biotech IPO priced at $17 per share - underwriter | Reutersreuters.com · Apr 2015

Berkeley's Aduro Biotech Banks $51.4 Million - BioSpacebiospace.com · Jan 2015

Novartis treats Aduro to funding and partnership -globalventuring.com

Frequently asked questions

What does Aduro Biotech do?: Aduro Biotech was a Berkeley, CA clinical-stage biopharmaceutical company developing cancer immunotherapies, including STING-pathway agonists and Listeria-based vaccine platforms derived from UC Berkeley research.
Who are Aduro Biotech's investors?: Aduro Biotech's investors include Foresite Capital, ACCELERATOR LIFE SCIENCE PARTNERS, Franklin Templeton, OrbiMed.
How much funding has Aduro Biotech raised?: Aduro Biotech has disclosed $92M raised across 2 rounds.
Who acquired Aduro Biotech?: Aduro Biotech was acquired by Chinook Therapeutics.
Where is Aduro Biotech headquartered?: Aduro Biotech is headquartered in Berkeley, US.